Various approaches have been explored for targeting CD133 on CSCs, including (i) gene therapy that uses CD133-targeted vectors to deliver therapeutic genes to CSCs, (ii) monoclonal antibodies (mAb) that specifically recognize and bind to CD133 and other immunological strategies, (iii) nanoparticles or nanoliposomes which can deliver therapeutic agents to the cells expressing CD133 selectively, and (iv) oligonucleotide therapeutics or chemotherapeutics which, by decreasing the level of CD133, reduce the cancer cell stemness property. Here, PROM1 is linked to cancer.